Bayer Warning Letters Reinforce FDA Ban On Supplement/Drug Combinations
This article was originally published in The Tan Sheet
Executive Summary
FDA warns Bayer HealthCare that its two products combining aspirin with dietary supplement ingredients are unapproved new drugs
You may also be interested in...
US FDA Suggests Adding Antioxidants To Drug Formulations To Mitigate Nitrosamine Risks
Agency recommends “mitigation strategies” also including designing formulations that incorporate excipients such as sodium carbonate which modify the micro-environment to neutral or basic pH.
P&G Wraps Launch Of Super C Supplement Brand In Co-Packaging With DayQuil And NyQuil OTCs
P&G could be using a door left open in FDA’s 2015 proposed rule that questioned the safety of offering co-packaged supplements and drugs. With OTC drug and supplement firms always looking to drive sales growth, competitors large and small could follow P&G through the door.
OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule
Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN trade group encourages FDA to allow. FDA will determine on a case-by-case basis whether already available co-packaged OTCs and supplements violate a proposed rule on drug co-packaging.